Sara Verdura

17PUBLICATIONS
33CO-AUTHORS
Cancer diagnosisMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Dec 23, 2022
Metabolomic and Mitochondrial Fingerprinting of the Epithelial-to-Mesenchymal Transition (EMT) in Non-Tumorigenic and Tumorigenic Human Breast Cells.

Elisabet Cuyàs, Salvador Fernández-Arroyo, Sara Verdura

|Dec 23, 2022
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors.

Sara Verdura, Jose Antonio Encinar, Eduard Teixidor

|Sep 09, 2022
Nutritional Niches of Cancer Therapy-Induced Senescent Cells.

Àngela Llop-Hernández, Sara Verdura, Elisabet Cuyàs

|Sep 09, 2022
Silibinin Suppresses the Hyperlipidemic Effects of the ALK-Tyrosine Kinase Inhibitor Lorlatinib in Hepatic Cells.

Sara Verdura, José Antonio Encinar, Salvador Fernández-Arroyo

|Jan 21, 2022
Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin.

Joaquim Bosch-Barrera, Ariadna Roqué, Eduard Teixidor

|Aug 27, 2021
Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer.

Joaquim Bosch-Barrera, Sara Verdura, José Carlos Ruffinelli

Pageof 3

Frequent Collaborators

16 joint publications

Javier A Menendez

9 joint publications

Elisabet Cuyàs

8 joint publications

Joaquim Bosch-Barrera

4 joint publications

José Antonio Encinar